PHIO (Phio Pharmaceuticals) Current Accrued Expense: $0.74 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHIO Phio Pharmaceuticals Corp PHIO
28 GF Score
Price $1.09
! 2 Warning Signs
View Full Analysis

What is Phio Pharmaceuticals Current Accrued Expense?

Phio Pharmaceuticals PHIO 28 Current Accrued Expense is $0.74 Mil as of Jun. 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Phio Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.74 Mil.

Phio Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($0.91 Mil) to Mar. 2026 ($0.69 Mil) but then increased from Mar. 2026 ($0.69 Mil) to Jun. 2026 ($0.74 Mil).

Phio Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($0.72 Mil) to Dec. 2024 ($0.76 Mil) and increased from Dec. 2024 ($0.76 Mil) to Dec. 2025 ($0.91 Mil).

Phio Pharmaceuticals Current Accrued Expense Related Terms

Phio Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Phio Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phio Pharmaceuticals Current Accrued Expense Chart

Phio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 0.62 0.72 0.76 0.91

Phio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.73 0.91 0.69 0.74
PHIO
28GF Score
Phio Pharmaceuticals Corp PHIO
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phio Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.74 Mil mean?
Phio Pharmaceuticals (PHIO) has a Current Accrued Expense of $0.74 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Phio Pharmaceuticals and its competitors.
Is Phio Pharmaceuticals' Current Accrued Expense too high?
Phio Pharmaceuticals' current Current Accrued Expense is $0.74 Mil. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' Current Accrued Expense compare to CALC and INTS?
Phio Pharmaceuticals' Current Accrued Expense of $0.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Phio Pharmaceuticals and its competitors. Phio Pharmaceuticals's current Current Accrued Expense is $0.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current Current Accrued Expense of $0.74 Mil. The current Current Accrued Expense is $0.74 Mil. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current Current Accrued Expense is $0.74 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phio Pharmaceuticals Business Description

Address 411 Swedeland Road, Suite 23-1080, King of Prussia, PA, USA, 19406
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score

Get the complete analysis for PHIO

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.09
Price